niacinamide and Lymphoma, B-Cell studies

niacinamide and Lymphoma, B-Cell

niacinamide has been researched along with Lymphoma, B-Cell in 2 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.

Research Excerpts

Excerpt	Relevance	Reference
" Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma."	3.83	Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. ( Barassi, C; Bernasconi, E; Bertoni, F; Cascione, L; Gaudio, E; Goodstal, S; Kwee, I; Ponzoni, M; Rinaldi, A; Stathis, A; Tarantelli, C; Targa, A; Zucca, E, 2016)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

2 (100.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Tarantelli, C	2
Zhang, L	1
Curti, E	1
Gaudio, E	2
Spriano, F	1
Priebe, V	1
Cascione, L	2
Arribas, AJ	1
Zucca, E	2
Rossi, D	1
Stathis, A	2
Bertoni, F	2
Kwee, I	1
Barassi, C	1
Bernasconi, E	1
Rinaldi, A	1
Ponzoni, M	1
Targa, A	1
Goodstal, S	1

Studies

Tarantelli, C

Zhang, L

Curti, E

Gaudio, E

Spriano, F

Priebe, V

Cascione, L

Arribas, AJ

Zucca, E

Rossi, D

Stathis, A

Bertoni, F

Kwee, I

Barassi, C

Bernasconi, E

Rinaldi, A

Ponzoni, M

Targa, A

Goodstal, S

Other Studies

2 other studies available for niacinamide and Lymphoma, B-Cell

Article	Year
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. Haematologica, 2019, Volume: 104, Issue:7 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bridge	2019
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cell Line, Tumor; Class I Phosphatidylinosito	2016

Article

Year

The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.

Haematologica, 2019, Volume: 104, Issue:7

Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bridge

2019

Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.

Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cell Line, Tumor; Class I Phosphatidylinosito

2016